You are here: Industry Insights > Baricitinib

News List

New England Journal of Medicine publishes COVID-19 treatment trial results worldpharmanews
January 18, 2021
A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results ...
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine prnewswire
December 14, 2020
Eli Lilly and Company and Incyte announced that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) ...
Scientists find five key genes are linked to severe COVID-19 expresspharma
December 14, 2020
The genes - called IFNAR2, TYK2, OAS1, DPP9 and CCR2 – partially explain why some people become desperately sick with COVID-19.
Baricitinib Receives EUA for Hospitalized Patients with COVID-19 americanpharmaceuticalreview
December 07, 2020
Eli Lilly and Company and Incyte announced the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination with remdesivir in hospitalized adult ...
Trial to compare dexamethasone and baricitinib in hospitalised COVID-19 patients europeanpharmaceuticalreview
November 27, 2020
The fourth iteration of the COVID-19 treatment trial will determine whether remdesivir plus baricitinib or dexamethasone, is more effective at promoting recovery from COVID-19.
FDA grants EUA for Lilly and Incyte’s baricitinib for Covid-19 treatment pharmaceutical-technology
November 23, 2020
The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for Eli Lilly and Company and Incyte’s baricitinib in combination with remdesivir in hospitalised patients with Covid-19.
Olumniant (barcitinab) from Eli Lilly gets EUA from US FDA for COVID-19 treatment expresspharma
November 20, 2020
The US Food and Drug Administration (USFDA) issued an emergency use authorisation (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults and pediatric ...
Lilly, Incyte tout new baricitinib data in eczema pharmatimes
November 05, 2020
Eli Lilly and Incyte showcased new data for their JAK inhibitor baricitinib in eczema at the virtual European Academy of Dermatology and Venereology (EADV) congress on Saturday.
Lilly, Incyte Release Information on Baricitinib, Remdesivir Combination for COVID-19 americanpharmaceuticalreview
October 15, 2020
Eli Lilly and Company and Incyte are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir.
Baricitinib, Remdesivir Trial Reduces Recovery Time in Hospitalized COVID-19 Patients americanpharmaceuticalreview
September 21, 2020
Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Previous page 1 2 3 4 5 Next page